168 related articles for article (PubMed ID: 36497449)
1. Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
van Wagensveld L; van Baal JOAM; Timmermans M; Gaillard D; Borghuis L; Coffelt SB; Rosenberg EH; Lok CAR; Nijman HW; Kooreman LFS; Sanders J; de Bruijn M; Wessels LFA; van der Wiel R; Rausch C; Broeks A; Kruitwagen RFPM; van der Aa MA; Sonke GS; Schouten PC; Van de Vijver KK; Horlings HM
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497449
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
3. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
5. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling Comparison of Germline
Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q
Front Oncol; 2020; 10():583314. PubMed ID: 33194720
[No Abstract] [Full Text] [Related]
7. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
9. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Fumet JD; Lardenois E; Ray-Coquard I; Harter P; Joly F; Canzler U; Truntzer C; Tredan O; Liebrich C; Lortholary A; Pissaloux D; Leary A; Pfisterer J; Eeckhoutte A; Hilpert F; Fabbro M; Caux C; Alexandre J; Houlier A; Sehouli J; Sohier E; Kimmig R; Dubois B; Spaeth D; Treilleux I; Frenel JS; Herwig U; Le Saux O; Bendriss-Vermare N; du Bois A
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267497
[TBL] [Abstract][Full Text] [Related]
10. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
[TBL] [Abstract][Full Text] [Related]
11. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
12. Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; ; Serra V; Waring P; Lim E; Caldon CE
NPJ Breast Cancer; 2021 Aug; 7(1):111. PubMed ID: 34465787
[TBL] [Abstract][Full Text] [Related]
13. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
14. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
[TBL] [Abstract][Full Text] [Related]
15. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
18. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT; Drapkin R
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]